Neoral®

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, University of Saskatchewan

Conditions

Cardiovascular DiseaseCardiovascular OutcomesKidney Transplant RecipientsKidney TransplantationRenal Transplantation

Phase 2

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

CompletedNCT01596062

Novartis PharmaceuticalsRenal Transplantation

Start: 2012-03-31End: 2013-03-31Updated: 2014-07-25

Phase 4

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

WithdrawnNCT02058875

University of SaskatchewanCardiovascular Disease, Cardiovascular Outcomes, Kidney Transplantation +1

Start: 2014-02-28End: 2015-10-31Updated: 2017-01-09

Related Papers

CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen

Transplant International2015-09-157 citations